22 February 2021
Visiongain has published a new report on Primary Immunodeficiency Market Report 2021-2031: Forecasts By Type (Antibody Deficiency, Cellular Deficiency, and Innate Immune), By Treatment Type (Immunoglobulin replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy, and Others), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Primary Immunodeficiency market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Primary Immunodeficiency market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Primary Immunodeficiency Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Primary Immunodeficiency market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Primary Immunodeficiency Disease (PIDD) around the World
The burden of primary immunodeficiency disease (PIDD) is increasing very rapidly around the world, and it is expected to continuously rise over the forecast period. Primary immunodeficiency disease (PIDD) used to reduce the immune system, causes health problems and infection to occur more easily.
Primary immunodeficiency disease (PIDD) is mostly inherited or due to mutations in the genetic code. The increasing prevalence of primary immunodeficiency disease (PIDD) is creating a huge demand for the primary immunodeficiency treatment. Due to the increasing prevalence of primary immunodeficiency disease (PIDD) around the world is working as a driver for the primary immunodeficiency market.
Increasing Therapeutic Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders
The burden of primary immunodeficiency disease (PIDD) has guided top leading manufactures to increase their research and development activities for Primary Immunodeficiency. Research and development activities for new technology for primary immunodeficiency are helping to increase adoption of novel therapeutic in primary immunodeficiency. Research and development activities in primary immunodeficiency disease (PIDD) is improvising treatment options, making great strides, and increasing quality of life for people suffering from primary immunodeficiency disease. Research and development activities are targeting towards the specific immunodeficiency and which can include transplant (stem cell, bone marrow, and thymus), immunoglobulin (antibody) replacements, prevention of antibiotics and strategies to manage autoimmune disease. Currently, many of the manufacturers are launching their product portfolios in primary immunodeficiency which is expected to fulfil demand and to work as a driver for the market.
Top companies (Baxter International, Inc., Shire, CSL Behring, and Kedrion Biopharma Inc.) constitute more than XX% share of the global Primary Immunodeficiency market. Other companies profiled in the report include: Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc., Biotest AG, Sanquin, and LFB SA Some of the key developments are listed below:
● In 2019, Grifols has launched XEMBIFY (immune globulin subcutaneous human-klhw), which is an immunoglobulin (IG). XEMBIFY is specially developed for the treatment of primary immunodeficiency (PI) in patients 2 years of age and older. The launch will help the company widen revenue generation from a market focused product portfolio.
● In 2016, Shire plc launched CUVITRU [Immune Globulin Subcutaneous (Human). CUVITRU is specially designed for treatment of pediatric and adult patients suffering with primary immunodeficiency (PI). The launch will help the company to increase revenue generation in the primary immunodeficiency market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global precision medicine market was valued at US$63,333 million in 2021 and is projected to grow at a CAGR of 10.8% during the forecast period 2022-2032.
05 July 2022
The global biologics market was valued at US$382.85 billion in 2022 and is projected to grow at a CAGR of 8.82% during the forecast period 2022-2032.
04 July 2022
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.